Search Results - "M. Pontone"

The Parkinson Anxiety Scale (PAS): Development and validation of a new anxiety scale by Leentjens, Albert F.G., Dujardin, Kathy, Pontone, Gregory M., Starkstein, Sergio E., Weintraub, Daniel, Martinez-Martin, Pablo

“…ABSTRACT Existing anxiety rating scales have limited construct validity in patients with Parkinson's disease (PD). This study was undertaken to develop and…”
Get full text

Efficacy and tolerability of antidepressants in Parkinson's disease: A systematic review and network meta‐analysis by Mills, Kelly A., Greene, M. Claire, Dezube, Rebecca, Goodson, Carrie, Karmarkar, Taruja, Pontone, Gregory M.

“…Objective To systematically review and analyze the efficacy and tolerability of different antidepressant pharmacologic treatments for depressive symptoms in…”
Get full text

NPTX2 in Cerebrospinal Fluid Predicts the Progression From Normal Cognition to Mild Cognitive Impairment by Soldan, Anja, Oh, Sungtaek, Ryu, Taekyung, Pettigrew, Corinne, Zhu, Yuxin, Moghekar, Abhay, Xiao, Mei-Fang, Pontone, Gregory M, Albert, Marilyn, Na, Chan-Hyun, Worley, Paul

“…This study examined whether cerebrospinal fluid (CSF) baseline levels of the synaptic protein NPTX2 predict time to onset of symptoms of mild cognitive…”
Get full text

Unusual clinical manifestation and challenging serological interpretation of syphilis: insights from a case report by Magri, F, Donà, M. G, Panetta, C, Pontone, M, Pimpinelli, F, Cameli, N, Cristaudo, A, Zaccarelli, M, Latini, A

“…Abstract Background The clinical manifestations of recent syphilis can be variable, with typical and atypical patterns. Several conditions may cause atypical…”
Get full text

Immunogenicity and safety of anti‐SARS‐CoV‐2 BNT162b2 vaccine in psoriasis patients treated with biologic drugs by Cristaudo, A., Graceffa, D., Pimpinelli, F., Sperati, F., Spoletini, G., Bonifati, C., Pellini, R., Lora, V., Pontone, M., Di Bella, O., Bracco, D., Morrone, A.

Get full text

Neuropsychiatric Complications of Parkinson Disease Treatments: Importance of Multidisciplinary Care by Taylor, Jacob, M.D., M.P.H, Anderson, William S., M.A., M.D., Ph.D, Brandt, Jason, Ph.D, Mari, Zoltan, M.D, Pontone, Gregory M., M.D., M.H.S

“…Although Parkinson disease (PD) is defined clinically by its motor symptoms, it is increasingly recognized that much of the disability and worsened quality of…”
Get full text

False negative RPR test with prozone phenomenon in an HIV‐negative man with secondary syphilis by Sernicola, A., Maddalena, P., La Greca, I., Donà, M.G., Salvi, M., Garelli, V., Stingone, C., Gianserra, L., Giuliani, E., Pontone, M., Pimpinelli, F., Latini, A.

Get full text

Predictors of anxiety in early-stage Parkinson's disease – Results from the first two years of a prospective cohort study by Rutten, Sonja, van der Ven, Peter M., Weintraub, Daniel, Pontone, Gregory M., Leentjens, Albert F.G., Berendse, Henk W., van der Werf, Ysbrand D., van den Heuvel, Odile A.

“…Anxiety has a negative impact on daily functioning and quality of life in patients with Parkinson's disease (PD). This study aims at assessing which…”
Get full text

Anxiety Has Specific Syndromal Profiles in Parkinson Disease: A Data-Driven Approach by Starkstein, Sergio E., M.D., Ph.D, Dragovic, Milan, Ph.D, Dujardin, Kathy, Ph.D, Marsh, Laura, M.D, Martinez-Martin, Pablo, M.D., Ph.D, Pontone, Gregory M., M.D, Richard, Irene H., M.D, Weintraub, Daniel, M.D, Leentjens, Albert F.G., M.D., Ph.D

“…Background Anxiety symptoms are common in Parkinson disease (PD). Recent evidence suggests that anxiety syndromes as encountered in clinical practice may not…”
Get full text

Effect of STN DBS on vesicular monoamine transporter 2 and glucose metabolism in Parkinson's disease by Smith, Gwenn S., Mills, Kelly A., Pontone, Greg M., Anderson, W. Stanley, Perepezko, Kate M., Brasic, James, Zhou, Yun, Brandt, Jason, Butson, Christopher R., Holt, Daniel P., Mathews, William B., Dannals, Robert F., Wong, Dean F., Mari, Zoltan

“…Deep brain stimulation (DBS) is an established treatment for Parkinson's Disease (PD). Despite the improvement of motor symptoms in most patients by…”
Get full text

Clinical Markers of Anxiety Subtypes in Parkinson Disease by Broen, Martinus P. G., Leentjens, A. F. G., Hinkle, J. T., Moonen, A. J. H., Kuijf, M. L., Fischer, N. M., Perepezko, K., Bakker, A., Pontone, G. M.

“…Objective: The aim of this work was to investigate marker profiles for proposed anxiety subtypes in Parkinson disease (PD). Methods: We used the persistent…”
Get full text

Visual Hallucinations in Neurodegenerative Diseases: Focus on Selective Tissue Vulnerability by Hinkle, Jared, BS, Pontone, Gregory M, MD, MHS

“…Hinkle and Pontone discuss the visual hallucinations in neurodegenerative diseases. In current issue it shows that neuronal loss in the superior colliculus…”
Get full text

Levetiracetam for the treatment of mild cognitive impairment in Parkinson’s disease: a double-blind controlled proof-of-concept trial protocol by Dissanayaka, Nadeeka, Pourzinal, Dana, Byrne, Gerard J, Yang, Jihyun, McMahon, Katie L, Pontone, Gregory M, O'Sullivan, John D, Adam, Robert, Littleford, Roberta, Chatfield, Mark, Lehn, Alexander, Mari, Zoltan, Bakker, Arnold

“…Abstract Background Mild memory impairment, termed amnestic mild cognitive impairment (aMCI), is associated with rapid progression towards dementia in…”
Get full text

Pharmacologic Treatment of Anxiety Disorders in Parkinson Disease by Pontone, Gregory M., M.D, Williams, James R., Ph.D, Anderson, Karen E., M.D, Chase, Gary, Ph.D, Goldstein, Susanne R., M.D, Grill, Stephen, M.D., Ph.D, Hirsch, Elaina S., M.S, Lehmann, Susan, M.D, Little, John T., M.D, Margolis, Russell L., M.D, Palanci, Justin, B.S, Rabins, Peter V., M.D., M.P.H, Weiss, Howard D., M.D, Marsh, Laura, M.D

“…Objective Neither best practices nor an evidence base for the pharmacologic treatment of anxiety in Parkinson disease (PD) has been established. This study…”
Get full text

Electrochemotherapy as palliative treatment in patients with recurrent and/or metastatic head and neck tumours: features analysis for an early determination of the partial responsive patients by Maglitto, F, Salzano, G, Longo, F, Di Bernardo, E, D'Alessio, V, Fusco, R, Aversa, C, Pavone, E, Pontone, M, Marciano, M L, Togo, G, De Fazio, G R, Ordano, D, Maglione, M G, Vaira, L A, Bergonzani, M, Salzano, F A, Maiolino, P, Califano, L, Ionna, F, Perri, F

“…The aim of this study was to identify features mainly involved in determining the partial response (PR) to the Electrochemotherapy (ECT) in patients with…”
Get more information

Invited Perspective on the “Annual Prevalence of Use of Potentially Inappropriate Medications for Treatment of Affective Disorders in Parkinson's Disease” by Pontone, Gregory M.

“…Affective disorders, anxiety, and depression, are the most prevalent neuropsychiatric disorders in Parkinson's disease (PD) and have a negative impact on…”
Get full text

Optimal Treatment of Depression and Anxiety in Parkinson's Disease by Pontone, Gregory M., Mills, Kelly A.

“…•What is the primary question addressed by this study? This article discusses the optimal treatment of anxiety and depression in Parkinson's disease.•What is…”
Get full text

Is Hoarding Behavior Driving the Association Between Obsessive-Compulsive Disorder in Elderly Parkinson Disease Patients? by Pontone, Gregory M.

“…Monaco et al found additional evidence for the second peak in that elderly whether healthy or suffering from Parkinson disease (PD) had an unexpectedly high…”
Get full text

An association between bipolar disorder and Parkinson disease: When mood makes you move by Pontone, Gregory M, Koch, Giacomo

Get full text

Designing a new scale to measure anxiety symptoms in Parkinson's disease: item selection based on canonical correlation analysis by Martinez-Martin, P., Rojo-Abuin, J. M., Dujardin, K., Pontone, G. M., Weintraub, D., Forjaz, M. J., Starkstein, S., Leentjens, A. F. G.

“…Background and purpose The lack of appropriate measures has hindered the research on anxiety syndromes in Parkinson's disease (PD). The objective of the…”
Get full text